Literature DB >> 16772868

Microarray-based analysis of spinal versus intracranial meningiomas: different clinical, biological, and genetic characteristics associated with distinct patterns of gene expression.

José María Sayagués1, María Dolores Tabernero, Angel Maíllo, Osvaldo Trelles, Ana Belén Espinosa, Maria Eugenia Sarasquete, Marta Merino, Ana Rasillo, Jaime Fernandez Vera, Angel Santos-Briz, Enrique de Alava, Maria Carmen Garcia-Macias, Alberto Orfao.   

Abstract

It has long been recognized that spinal meningiomas show particular clinical and histological features. Here, we compare the clinico-biological characteristics as well as the genetic abnormalities and patterns of gene expression of spinal and intracranial meningiomas. Fourteen spinal and 141 intracranial meningioma patients were analyzed at diagnosis. In all tumors, interphase fluorescence in situ hybridization (iFISH) studies were performed for the detection of quantitative abnormalities for 11 different chromosomes. Additionally, microarray analyses were performed on a subgroup of 18 histologically benign meningiomas (7 spinal and 11 intracranial). Upon comparison with intracranial tumors, spinal meningiomas showed a marked predominance of psammomatous and transitional tumors (p = 0.001), together with a higher proportion of cases displaying a single tumor cell clone by iFISH (p = 0.004). In 86% of the spinal versus 56% of the intracranial tumors (p = 0.01), the ancestral tumor cell clone detected showed either absence of any chromosomal abnormality or monosomy 22/22q- alone. Analysis of gene expression profiles showed differential expression between spinal and intracranial meningiomas for a total of 1555 genes, 35 of which allowed a clear distinction between both tumor types. Most of these 35 genes (n = 30) showed significantly higher expression among spinal tumors and corresponded to genes involved in signal transduction pathways, which did not show a significantly different expression according to tumor histopathology. In summary, we show the occurrence of unique patterns of genetic abnormalities and gene expression profiles in spinal as compared to intracranial meningiomas that provide new insights into the molecular pathways involved in the tumorigenesis and progression of spinal meningiomas, and could help explain their particular clinical and histological features.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16772868     DOI: 10.1097/01.jnen.0000229234.13372.d8

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  12 in total

Review 1.  Updates in the management of intradural spinal cord tumors: a radiation oncology focus.

Authors:  Rupesh Kotecha; Minesh P Mehta; Eric L Chang; Paul D Brown; John H Suh; Simon S Lo; Sunit Das; Haider H Samawi; Julia Keith; James Perry; Arjun Sahgal
Journal:  Neuro Oncol       Date:  2019-06-10       Impact factor: 12.300

Review 2.  Pediatric meningioma: current approaches and future direction.

Authors:  Rishi S Kotecha; Reimar C Junckerstorff; Sharon Lee; Catherine H Cole; Nicholas G Gottardo
Journal:  J Neurooncol       Date:  2011-01-04       Impact factor: 4.130

3.  Comparative clinical and genomic analysis of neurofibromatosis type 2-associated cranial and spinal meningiomas.

Authors:  Alexander Pemov; Ramita Dewan; Nancy F Hansen; Settara C Chandrasekharappa; Abhik Ray-Chaudhury; Kristine Jones; Wen Luo; John D Heiss; James C Mullikin; Prashant Chittiboina; Douglas R Stewart; Ashok R Asthagiri
Journal:  Sci Rep       Date:  2020-07-28       Impact factor: 4.379

Review 4.  Recent advances in intradural spinal tumors.

Authors:  Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

Review 5.  Spinal cord tumours: advances in genetics and their implications for treatment.

Authors:  Patricia L Zadnik; Ziya L Gokaslan; Peter C Burger; Chetan Bettegowda
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

6.  Specific genes expressed in association with progesterone receptors in meningioma.

Authors:  Elizabeth B Claus; Peter J Park; Rona Carroll; Jennifer Chan; Peter M Black
Journal:  Cancer Res       Date:  2008-01-01       Impact factor: 12.701

Review 7.  Gene expression profiling of meningiomas: current status after a decade of microarray-based transcriptomic studies.

Authors:  Mads Aarhus; Morten Lund-Johansen; Per Morten Knappskog
Journal:  Acta Neurochir (Wien)       Date:  2011-01-14       Impact factor: 2.216

8.  Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.

Authors:  Yiping Shen; Fabio Nunes; Anat Stemmer-Rachamimov; Marianne James; Gayatry Mohapatra; Scott Plotkin; Rebecca A Betensky; David A Engler; Jennifer Roy; Vijaya Ramesh; James F Gusella
Journal:  BMC Med Genomics       Date:  2009-07-09       Impact factor: 3.063

9.  Molecular signatures define two main classes of meningiomas.

Authors:  Lucia Helena Carvalho; Ivan Smirnov; Gilson S Baia; Zora Modrusan; Justin S Smith; Peter Jun; Joseph F Costello; Michael W McDermott; Scott R Vandenberg; Anita Lal
Journal:  Mol Cancer       Date:  2007-10-15       Impact factor: 27.401

10.  Pathogenic Huntingtin Repeat Expansions in Patients with Frontotemporal Dementia and Amyotrophic Lateral Sclerosis.

Authors:  Ramita Dewan; Ruth Chia; Jinhui Ding; Richard A Hickman; Thor D Stein; Yevgeniya Abramzon; Sarah Ahmed; Marya S Sabir; Makayla K Portley; Arianna Tucci; Kristina Ibáñez; F N U Shankaracharya; Pamela Keagle; Giacomina Rossi; Paola Caroppo; Fabrizio Tagliavini; Maria L Waldo; Per M Johansson; Christer F Nilsson; James B Rowe; Luisa Benussi; Giuliano Binetti; Roberta Ghidoni; Edwin Jabbari; Coralie Viollet; Jonathan D Glass; Andrew B Singleton; Vincenzo Silani; Owen A Ross; Mina Ryten; Ali Torkamani; Toshiko Tanaka; Luigi Ferrucci; Susan M Resnick; Stuart Pickering-Brown; Christopher B Brady; Neil Kowal; John A Hardy; Vivianna Van Deerlin; Jean Paul Vonsattel; Matthew B Harms; Huw R Morris; Raffaele Ferrari; John E Landers; Adriano Chiò; J Raphael Gibbs; Clifton L Dalgard; Sonja W Scholz; Bryan J Traynor
Journal:  Neuron       Date:  2020-11-26       Impact factor: 18.688

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.